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Abstract
Background: Identification of single nucleotide polymorphisms (SNPs) associated with gene expression levels, known as
expression quantitative trait loci (eQTLs), may improve understanding of the functional role of phenotype-associated SNPs
in genome-wide association studies (GWAS). The small sample sizes of some previous eQTL studies have limited their
statistical power. We conducted an eQTL investigation of microarray-based gene and exon expression levels in whole
blood in a cohort of 5257 individuals, exceeding the single cohort size of previous studies by more than a factor of 2.
Results: We detected over 19,000 independent lead cis-eQTLs and over 6000 independent lead trans-eQTLs, targeting
over 10,000 gene targets (eGenes), with a false discovery rate (FDR) < 5%. Of previously published significant GWAS
SNPs, 48% are identified to be significant eQTLs in our study. Some trans-eQTLs point toward novel mechanistic
explanations for the association of the SNP with the GWAS-related phenotype. We also identify 59 distinct blocks
or clusters of trans-eQTLs, each targeting the expression of sets of six to 229 distinct trans-eGenes. Ten of these
sets of target genes are significantly enriched for microRNA targets (FDR < 5%). Many of these clusters are associated in
GWAS with multiple phenotypes.
Conclusions: These findings provide insights into the molecular regulatory patterns involved in human physiology and
pathophysiology. We illustrate the value of our eQTL database in the context of a recent GWAS meta-analysis of
coronary artery disease and provide a list of targeted eGenes for 21 of 58 GWAS loci.
Background
Implementation of high-resolution genotyping has led to
a wave of genome-wide association studies (GWAS) of
hundreds of phenotypes relevant to human health and
disease [1]. Yet, the vast majority of the single nucleotide
polymorphisms (SNPs) from GWAS that are associated
with clinical traits and diseases reside in non-coding re-
gions [2, 3]. This means that most disease-associated
SNPs do not directly influence protein structure or func-
tion, but instead may act on phenotypes by affecting ex-
pression of local (cis) or distant (trans) gene targets
(eGenes). Thus, characterizing the relations of DNA se-
quence to RNA expression is a critical step toward a
better mechanistic understanding of disease, and ultim-
ately toward improvements in diagnosis, prevention, and
treatment. This endeavor begins with analysis of variation
in messenger RNA (mRNA) expression levels associated
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with genotypic variation to identify expression quantita-
tive trait loci (eQTLs) across the human genome [4].
The measurement of transcriptome-wide expression
levels has facilitated several genome-wide eQTL studies
[1, 4–8]. The sample sizes of some earlier eQTL studies,
however, may have limited their statistical power [9], al-
though a recent study [8] utilized a cohort of more than
2000 individuals and a previous study [5] used multiple
cohorts totaling over 5000 individuals in meta-analysis.
Of note, prior studies did not report results trans-eQTLs
genome-wide. We report results of a microarray-based
genome-wide eQTL study, considering both cis and
trans elements, in whole blood samples from over 5000
participants in the Framingham Heart Study (FHS) [10, 11],
a multi-generational community-based prospective study.
To our knowledge, our study utilizes the largest, single-site
study to date, and reports both gene-level and exon-level
cis-eQTLs and trans-eQTLs genome wide.
Results
Characteristics of the study sample [10, 11] are provided
in Table 1. Participants in the FHS Third Generation co-
hort were about 20 years younger than those of the FHS
Offspring cohort at the time of blood collection for
RNA isolation. White blood cell counts and their pro-
portions also differed between the cohorts.
Out of 39 million imputed SNPs, we found 8.5 million
with a minor allele frequency (MAF) ≥ 0.01 and imput-
ation quality R2 ≥ 0.3 (See “Methods” for further details).
Of these, we identified 2.2 million cis-eQTLs and 160
thousand trans-eQTLs at a nominal false discovery rate
(FDR) < 0.05 (Table 2). We observed no inflation of the
genomic control factor [12] (λ = 0.986). The quantile-
quantile plot can be found in Additional file 1: Figure S1.
We determined that polymorphism-in-probe effects [13],
which occur when the variable position of a poly-
morphism overlaps an expression probe (Additional
file 1: Figure S2), were generally minor, possibly affecting
up to about 9.5% of the detected eGenes (see Additional
file 1: Supplementary Methods for details). Moreover,
these potential artifacts generally could be recognized
by inspection of the individual exon-level results corre-
sponding to that gene. Only one of the top 25 cis-
eQTL-transcript cluster pairs (C9orf78, Table 4) was
flagged for this artifact and that pair was not replicated
in external datasets.
Recognizing that many of the significant eQTLs were
in linkage disequilibrium (LD) with stronger, nearby
eQTLs, we pruned our result using a stepwise linear re-
gression procedure that identified a subset of the stron-
gest, independent “lead-eQTLs” for each genetic region
(see “Methods”). We found over 19,000 independent,
lead cis-eQTLs and almost 6000 independent, lead
trans-eQTLs, targeting over 10,000 cis- and almost 6000
thousand trans-eGenes. We found an eQTL for over half
of the 17,873 measured transcript clusters (Table 2,
Fig. 1, and Additional file 1: Figure S3). Use of a stricter
nominal cutoff of FDR < 0.0005 reduced the number of
independent cis-eQTLs and the number of targeted cis-
eGenes by about 8% (Table 2). The stricter cutoff had a
much larger effect on the number of trans-eGenes, redu-
cing them by almost fivefold.
Cis-eQTLs are frequently defined as targeting expres-
sion of genes within 1 megabase (Mb) of the transcrip-
tion start site (TSS). Others have noted that cis-eQTLs
may be detected beyond the 1 Mb threshold [8]. We
modified our definition of cis-eQTLs to include all
eQTLs falling in an uninterrupted block around the TSS,
provided there are no included gaps greater than 1 Mb
in size. Trans-eQTLs were defined as those that target
genes on other chromosomes or genes outside the con-
tiguous cis- blocks (see “Methods” for details). We found
long-range cis-eQTL blocks up to 10 Mb in width, e.g.
for gene BTN3A2 on chromosome 6. Such long-range
cis-eQTLs were found for 255 transcript clusters, 75 of
which, including BTN3A2, were located in the HLA
Table 1 Demographic characteristics
Characteristic Offspring cohort
(n = 2240)
Generation 3 cohort
(n = 3017)
P value*
Males (%) 45.1% 46.8% 0.2291
Age, in years 66.4 ± 9.0 46.4 ± 8.8 1.36E-895
White blood cell count (× 103/mL)b 6.2 ± 1.3 6.0 ± 1.5 2.57E-7
Neutrophil (%)b 59.7 ± 7.9 58.7 ± 7.7 8.63E-7
Lymphocyte (%)b 27.1 ± 7.5 28.8 ± 6.9 2.20E-17
Monocyte (%)b 9.2 ± 1.9 8.6 ± 2.0 5.79E-22
Eosinophil (%)b 3.3 ± 1.6 3.1 ± 1.9 0.0039
Basophil (%)b 0.8 ± 0.2 0.8 ± 0.3 0.0019
Platelet count (× 103/mL)b 253.0 ± 36.5 247.5 ± 51.5 6.34E-6
*P values are from two-sample t-tests. For sex phenotype, the P value is from Fisher’s exact test
bCBC values are imputed based on actual measurements of 2274 samples within the Generation 3 cohort
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region of chromosome 6; 22 were identified on chromo-
some X including gene ITM2A (8.7 Mb width), and 18
were found on chromosome 3 including gene UBA7
(7 Mb width). While some blocks may result from ex-
tended LD structure in the genome, others may point to
extended patterns of regulatory sites. Our results sup-
port the conclusions of Kirsten et al. [8] who observed
cis- associations extending to up to 5 Mb. In each
contiguous region of eQTLs, we defined the “lead”
eQTL as that which displayed the strongest association
with its target transcript cluster, as defined by P value.
The lead eQTL is the most likely causal eQTL, and for
cis-eQTLs, its position relative to the TSS could be read-
ily studied. For some eQTL blocks, we found that not all
significant eQTLs were in LD with the primary lead
eQTL but that secondary, independent lead eQTLs also
Table 2 Number of independent, significant eQTL-gene pairs with number of unique eQTLs or unique genes with P value corresponding
to indicated FDR cutoff
Pair type eQTL-TranscriptCluster pairs Unique eQTLs Independent pairs Independent unique
lead eQTLs
Unique genesa
(% available)
P value cutoff
Nominal FDR < 0.05
Cis 4,285,456 2,221,013 19,613 19,239 10,327 (58%) 1.00 E-4*
Trans 216,169 91,559 6741 5749 4958 (28%) 1.41 E-7
Nominal FDR < 0.0005
Cis 3,698,429 2,008,734 17,452 17,119 9232 (52%) 1.78E-5
Trans 116,960 52,426 1464 888 1025 (6%) 8.82E-10
Available 1.521 E11 8,510,936 1.521 E11 8,510,936 17,873 (100%)
*P value cutoff corresponding to FDR. Upper bound P value for pairs retained in computation was 1E-4, therefore highest attained FDR for cis-eQTLs was 0.0024
aTranscript cluster ID is used as a proxy for genes. Only 244 genes were represented by more than one Transcript cluster IDs. Approximately 270 Transcript cluster
IDs could not be assigned to an Entrez Gene entry
Fig. 1 Genomic eQTL location vs. transcript cluster location for highly significant eQTL-gene pairs (FDR < 1E-8). Bubble size is inversely proportional to
the FDR. The largest bubble indicates FDR < 1E-100
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could be found after accounting for the primary lead
eQTL. Stepwise regression, including primary and suc-
cessive independent lead eQTLs, determined a set of
mutually independent lead eQTLs for each block (see
“Methods” for details).
Benefits of a large cohort
Use of a very large cohort size for eQTL analysis pro-
vided obvious benefits in terms of greater statistical
power for discovery. To better quantify the value of co-
hort size, we considered whether the number of eGenes
detected in our study would be detected with a smaller
cohort. We repeated the full analysis using only the FHS
Offspring cohort subset (n = 2240) and separately, only
the FHS Third Generation cohort subset (n = 3017).
Overall (Additional file 1: Table S1), we found that as
the sample size dropped by roughly half, the number of
unique cis-eGenes fell roughly proportionately, while the
number of trans-eGenes declined to a much greater de-
gree. Conversely, we concluded that our large sample
size allowed for detection of many novel cis- and trans-
eGenes. We found that our full cohort allowed detection
of roughly 60% more cis-eGenes than did either smaller
cohort. The full cohort detected three times to five times
more trans-eGenes than did the smaller cohorts. It is
clear that even with the current large cohort size, we
have not yet detected all cis-eQTLs. We also found that
the number of lead eQTLs (primary and secondary) per
detected eGene increased using the full cohort (Addi-
tional file 1: Table S1). This demonstrates the power of
the larger cohort to detect possible multiple SNPs on
the pathways affecting expression.
As an example of the biological relevance of increasing
the number of detected eGenes, consider the SNP
rs1354034, a very strong GWAS hit for platelet count and
platelet volume [14]. Using the full cohort, we detected
136 trans-eGenes that are targeted by variation at this
locus. At least 27 of these genes are indeed known to be
platelet-specific [15]. Analysis restricted to the smaller
FHS Offspring cohort alone detected only 30 transcript
clusters, 11 of which are platelet specific. Thus, increasing
the sample size to include both FHS cohorts more than
doubled the list of platelet-related genes. Further, when we
consider the overlap of detected eQTLs with the GWAS
catalog (see “Clinical relevance,” below), we found that
restricting the analysis to the smaller cohort reduced the
overlap by 33%. Thus, the full, large cohort clearly has
greater power to annotate clinically relevant SNPs.
Replication and validation
We assessed our results by three methods: (1) internal
validation; (2) replication of previously published results
(replication rate); and (3) the proportion of our results
seen in earlier published studies (validation rate). Splitting
our large sample into two roughly equally sized cohorts
demonstrated an internal replication rate of 75% for
cis-eQTL-transcript cluster pairs and 41% for trans-
eQTL-transcript cluster pairs at the gene level, with 100%
of the replicated pairs showing the same direction of
change in expression (Additional file 1: Table S2).
We were able to replicate high proportions of eQTLs
published in two previous eQTL studies even though
they used different expression platforms. We replicated
69% of eligible cis-eQTL and 62% of trans-eQTL-tran-
script cluster pairs reported by Westra et al. [5] and 66%
of cis-eQTL and 29% of trans-eQTL-transcript cluster
pairs reported by Liang et al. [6]. We were able to repli-
cate 59% of cis- and 56% of trans- results from a more
recent study that used RNA-sequencing (RNAseq)
methodology to report lead eQTLs [7]. These rates are
13 and 300,000 times the expected rates, for cis- and
trans-eQTLs, respectively. The P values for these rates
are <1E-200. We were able to replicate 36% of eligible
cis-eQTL-transcript cluster pairs and 5.2% of trans-
eQTL pairs from the largest, homogenous eQTL study
available to date [8]. The replication rates are 78 and
30,000 times the expected rates, for cis-eQTLs and
trans-eQTLs, respectively. The replication rates for the lat-
ter study might have been attenuated because of differences
in RNA source (peripheral blood mononuclear cells versus
whole blood) and use of different expression platforms
(Illumina HTarray versus the Affymetrix Exon array).
We explored external validation of our independent
eQTL-transcript cluster pairs in two published studies
and in seven datasets across multiple tissues in the
NCBI Molecular QTL Repository [2, 4–6] (referred to as
“Multiple studies” in Table 3) and in two more recent
studies [7, 8] (see “Methods” for details). As expected,
the cis external validation rates (Table 3) were lower
than our internal validation rates. For Multiple Studies,
we validated 54% of eligible lead cis-eQTL-transcript
cluster pairs from our study, but only validated 2% of
lead trans-eQTL results. The direction of effect matched
in 89% of validated pairs. The RNAseq-based eQTL
study of Battle et al. [7] reported only the lead variant
for each targeted transcript. Since we did not expect per-
fect alignment with our lead eQTLs, we relaxed our
matching criteria to count situations where our lead
eQTL was in strong LD (R2 > 0.8) with their lead variant.
Using this approach, we achieved external validation for
25% of our lead cis-eQTL-eGenes pairs but only for 4%
of our lead trans pairs. When comparing our results
with those of Kirsten et al. [8] using the same approach,
we validated 58% of our eligible, independent lead cis-
eQTLs and 6% of our trans-eQTLs. We observed that
85% of lead cis-eQTLs and 93% of lead trans-eQTLs
validated by Kirsten et al. [8] also showed the same
direction of effect as did our study. The detection rate
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and validated detection rate is dependent on the number
of available probesets for the transcript, rising to a plat-
eau when more than about 20 probesets are available
(Additional file 1: Figure S4). Imperfect validation rates
reflect a combination of factors: the potentially novel
discoveries in our dataset as a result of the larger homo-
geneous sample size, the use of multiple genotyping
chips of lower density in the comparison studies, the
lack of imputation in one other study, differences among
populations, and difficulties in accurately comparing
transcript expression levels measured with different
platforms.
The top 25 lead cis-eQTL and trans-eQTL transcript
cluster pairs, ranked by percent of variance explained
(R2), are presented in Table 4. Illustrative box-plots for a
cis-eQTL and a trans-eQTL are given in Fig. 2. For the
top cis-eQTL gene pair (rs12231872 with CLEC12A)
more than half of the variation in expression of the
eGene was explained by the cis-eQTL. Likewise, the top
trans-eQTL (rs6592965) explained over 22% of the vari-
ation in expression of the corresponding trans-eGene
(SLC38A5). Interestingly, ten of the 25 (or 40%) top cis-
eQTLs were in significant LD with or were themselves
GWAS hits (at P < 5E-8), providing support for the idea
that genetically determined effects on gene expression
have phenotypic consequences. Perhaps more note-
worthy is the finding that 17 of the 25 (68%) top trans-
eQTLs were also either GWAS hits or in significant LD
with GWAS hits. Again, this supports the notion that
not just cis-eQTL but also trans-eQTL effects may ex-
plain the mechanism of action of these genetic variants.
We found external validation for 18 of 25 (72%) top cis-
eQTL-eGene pairs in at least one of four published data-
sets [5–8], a high rate that perhaps should be expected
for such prominent associations. We found evidence of
external validation for only six of 25 (24%) top trans-
eQTL pairs, perhaps because few published studies have
reported full genome-wide trans-eQTL results.
The Affymetrix Exon Array provides expression mea-
surements at the transcript cluster level, but also for in-
dividual exons within the transcript cluster. At the exon
level (Additional file 1: Table S3), we detected many of
the same cis-eQTLs for individual probesets of the same
genes identified at the gene-level. The top exon-level
trans-eQTLs also duplicated many of the results seen at
the gene-level, including many trans-eQTLs found to be
part of trans-eQTL blocks or clusters (discussed in detail
below). However, the percentage of variance of expression
levels of these exons explained by their trans-eQTLs is
generally much higher than that for the corresponding
gene-level results, probably because the gene-level analysis
averages over multiple exons that demonstrate consider-
able variation.
Enrichment of lead eQTL location relative to gene
structure and neighborhood
A major goal of eQTL studies is to identify true gene
transcription regulatory elements. Previous analyses
[5, 7, 8] have shown a strong dependence of eQTL
position relative to the TSS and transcription end sites
(TES) of each gene. We analyzed 8475 protein-coding
eGenes with identifiable gene structure and without
suspicion of polymorphism-in-probe effects, to iden-
tify preferences for locations of all significant eQTLs
and of the lead eQTL. We found that lead eQTLs are
frequently (for 35% of eGenes) found in the tran-
scribed region of the gene, a ninefold enrichment
compared to elsewhere in the 2 Mb region centered
on the TSS (Additional file 1: Table S4). The lead
eQTL is also frequently (38%) in the upstream cis-
intergenic region, but less often than expected. The
lead eQTL is less frequently (28%) in the downstream
cis-intergenic region (Additional file 1: Table S4). The
distance from upstream lead eQTLs to the TSS follows
a multi-exponential decay curve with a median dis-
tance of about 27 kb. The distance downstream from
the TES to the lead eQTLs follows a similar multi-
exponential distribution with a slightly longer median
distance of about 31 kb. A graphical representation of
the observed distribution of lead eQTL locations is
given in Additional file 1: Figure S5. Within the tran-
scribed region, exonic locations are highly enriched
(25 fold) for lead eQTLs, more so than for intronic lo-
cations (12-fold). The first exon and the 5’- UTR are
Table 3 Number of independent, significant pairs validated in previous studies
Pair type Comparison study Eligible lead eQTL-gene pairsa Validated pairsa (rate) Expected pairs (rate)
Cis Multiple studies [2, 4–6] 10,584 5700 (54%) 90 (0.8%)
Battle et al. [7] 11,466 2911 (25%) 10 (0.08%)
Kirsten et al. [8] 11,179 6503 (58%) 919 (8%)
Trans Multiple studies [2, 4–6] 1777 40 (2%) 0.0007 (0%)
Battle et al. [7] 2596 102 (4%) 0.0001 (0%)
Kirsten et al. [8] 2337 135 (6%) 0.03 (0%)
aSee “Methods” and Additional file 1: Supplementary Methods for details
P values (comparing Validated to Expected pairs are based on Poisson distribution) are all <1E-200
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Table 4 Top 25 non-redundant gene level cis-eQTL and top 25 trans-eQTL-transcript cluster pairs
eQTL marker position Rs ID Transcript cluster ID Trans Chr Gene symbol R2 Beta Cluster number
Top Cis-eQTL pairs
12:10118747 rs12231872 3404530 R 12 CLEC12A 57% −0.15 [G]
15:48596713 rs74011998 G 3593065 15 SLC12A1 56% −0.15 [T]
5:96252589 rs2910686 H G 2821347 R 5 ERAP2 55% −0.11 [T]
1:207280764 rs12063500 G 2377165 R 1 C4BPA 54% −0.32 [C]
6:31238135 rs1050317 G 2948887 6 50% −0.3 [A]
6:32576341 rs9271093 G 4048241 R 6 HLA-DRB5 50% −0.45 [A]
22:42498204 rs12157818 3947310 R 22 C22orf32 49% 0.16 [C]
6:26354100 rs67509210 G 2899333 R 6 BTN3A2 48% 0.19 [G]
7:150480007 rs1985881 3079172 R 7 TMEM176B 48% −0.17 [C]
4:6697822 rs3822260 H G 2717078 4 S100P 48% 0.24 [C]
22:45744854 rs8136319 3948543 R 22 FAM118A 48% −0.2 [G]
6:167382449 rs434093 G 2984884 R 6 RNASET2 48% 0.12 [T] 21
1:17421764 rs2076613 2398820 1 PADI2 47% 0.08 [T]
X:109206541 rs2499412 3987029 X TMEM164 47% 0.11 [G]
4:47858518:ATAG_ 2768273 4 NFXL1 47% −0.1 [R]
5:64858687 rs432206 H 2859667 R 5 CENPK 47% −0.14 [C]
7:150478052 rs6464101 H 3031624 R 7 TMEM176A 47% −0.15 [G]
1:109706880 rs647294 H 2350489 R 1 KIAA1324 47% 0.14 [G]
6:32575544 rs9271061 G 4048265 R 6 HLA-DRB1 46% −0.55 [T]
5:102118794 rs2431321 H 2822215 R 5 PAM 46% −0.08 [T]
6:32603854 rs9272302 G 2903219 R 6 HLA-DRB6 46% −0.77 [C]
7:26952139 rs2960785 H 3042610 R 7 SKAP2 46% 0.08 [C]
1:43265985 rs2816599 2409069 R 1 CCDC23 45% −0.31 [C]
9:132588337 rs7470675 3227121 S 9 C9orf78 45% 0.17 [T]
7:75247329 rs1186222 3057370 R 7 HIP1 45% 0.09 [C]
Top Trans-eQTL Pairs
7:50427982 rs6592965 G 4007437 R X SLC38A5 22% 0.09 [G] 25
17:44026739 rs242562 H G 3767230 17 LRRC37A3 20% 0.16 [G]
3:30722412 rs3773654 3638566 15 PEX11A 16% –0.18 [G]
1:58992071 rs7520008 2414558 1 DAB1 12% 0.04 [T]
3:50078541 rs9814664 H G 3981931 X ZCCHC13 12% 0.11 [T] 9
7:50427982 rs6592965 G 2520069 R 2 C2orf88 11% 0.1 [G] 25
1:248039451 rs3811444 H G 3357237 R 11 JAM3 11% 0.08 [C] 4
3:49978069 rs6772095 H G 4024310 X SOX3 11% 0.06 [C] 9
16:69973655 rs4985461 2876543 5 TIFAB 11% –0.08 [G]
7:50427982 rs6592965 G 3724505 17 MYL4 9% 0.08 [G] 25
21:44473062 rs11700748 H G 3416019 12 PRR13 9% 0.1 [C] 56
5:50106439 rs32396 H G 2359431 1 LCE1F 8% 0.08 [G]
11:617537 rs2740380 G 3864107 19 PSG7 8% 0.13 [T]
3:49971514 rs7613875 H G 3693591 16 PRSS54 8% 0.06 [C] 9
3:50008566 rs6446189 G 3939154 22 RAB36 8% 0.05 [A] 9
3:56849749 rs1354034 H G 3724545 R 17 ITGB3 8% –0.08 [T] 10
11:108623805:CTAT_ 3504617 13 SKA3 8% –0.1 [R]
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especially enriched for lead eQTLs (45-fold) while
other exons, the 3’-UTR, the first intron and subse-
quent introns (21-fold, 20-fold, 11-fold, and 8-fold, re-
spectively) show lesser degrees of enrichment
(Additional file 1: Table S4). Thus, it is clear that lead
cis-eQTLs act preferentially through regulatory ele-
ments within the first exon, within the 5’-UTR or near
the TSS. We also analyzed just the secondary lead
eQTLs which show independent significant associa-
tions with about half of the targeted transcript clus-
ters. Again, the 5’-UTR again was maximally enriched
(30-fold) in these lead eQTLs. The pattern of enrich-
ment was nearly identical but somewhat weaker than
that for the primary lead eQTLs, This shows that sec-
ondary lead eQTLs also convey important information re-
garding functional sites.
Enrichment of lead eQTLs at regulator sites
To further explore the regulatory sites, we compared
our results to RegulomeDB [16], a summary of evidence
for a regulatory role for each SNP, based on DNAase
hypersensitivity, transcription factor binding sites, and
biochemically characterized regulatory promoter regions.
Specifically, we tested whether our lead cis-eQTLs exclud-
ing those targeting polymorphism-in-probe transcripts)
were enriched for regulatory roles (i.e. low RegulomeDB
scores) compared to other cis-SNPs within 1 Mb of each
transcript start site, having no such evidence. Results,
summarized in Additional file 1: Table S5, show strong
enrichment of regulatory evidence for all (primary
and secondary) lead cis-eQTLs (sevenfold enrich-
ment, P < 1E-89). The primary lead cis-eQTLs alone
showed a stronger enrichment (eightfold, P < 1E-69),
but with a minor attenuation in significance level.
This result suggests that lead eQTLs are indeed
identifying regulatory sites and that the primary lead
eQTLs are the most likely regulatory position in a
given neighborhood. Only a barely significant, two-
fold excess of lead trans-eQTLs were found with low
RegulomeDB scores, suggesting that at most a modest
fraction of trans-eQTLs are acting at known regulatory
sites.
Clusters of trans-eQTLs
Some trans-eQTLs are associated with multiple distant
transcripts and can be grouped into compact genomic
blocks or clusters (see “Methods”). Although such “regu-
latory hotspots” can arise from confounding factors such
as batch effects [17], we used methods that reduce or
avoid such spurious associations (see “Methods”). At the
gene level, we identified 59 distinct clusters of trans-
eQTLs, each targeting a set of six to 141 distant tran-
scripts (Table 5, Fig. 3). Studying the targets of these
clusters may illuminate the functional roles of these
eQTLs. For example, such trans-eQTL clusters may be a
result of downstream consequences of a variant within a
haplotype block [18]. The most prominent trans-eQTL
clusters are on chromosomes 3 and 17 (Clusters 10, 51,
and 52) and are associated with expression of platelet-
specific genes, such as CTTN, HIST1H3H, and MMD
[15, 19, 20]. SNPs in these clusters were reported to be
associated in GWAS [4] with platelet count and mean
platelet volume (e.g. rs1354034 and rs12485738 on
chromosome 3; rs10512472 and rs16971217 on chromo-
some 17) [21]. Variation in platelet count or volume
would likely cause changes in the proportion of RNA de-
rived from platelets in the whole blood sample and thus,
variation in the apparent expression levels of platelet as-
sociated genes. We found 13 platelet-related GWAS
clusters (Table 5, Additional file 1: Table S6), many of
which also had target gene sets enriched with platelet-
Table 4 Top 25 non-redundant gene level cis-eQTL and top 25 trans-eQTL-transcript cluster pairs (Continued)
17:33875262 rs8073060 H 3089102 R 8 EPB49 7% –0.05 [T] 51
3:56849749 rs1354034 H G 2735759 4 MMRN1 7% –0.07 [T] 10
11:55113534 rs75905900 G 3329983 11 PTPRJ 7% –0.05 [A]
6:170847101 rs75159687 2390976 1 LINC00115 7% –0.13 [T]
22:50027210 rs5769712 3581090 14 TMEM179 7% 0.06 [C] 58
7:50427982 rs6592965 G 3714729 R 17 MAP2K3 7% –0.05 [G] 25
22:50027210 rs5769712 3203199 9 TAF1L 6% 0.07 [C] 58
3:56849749 rs1354034 H G 2476510 2 LTBP1 6% –0.06 [T] 10
R2 - Percentage variance explained
Marker position is annotated as chromosome number:location in hg19 coordinate
Beta is regression estimate (log base 2 expression difference per dosage of effect allele), with effect allele in brackets. [R] refers to the reference allele for an
indel polymorphism
H = HapMap SNPs
G = in LD with GWAS SNPs as recorded in the NHGRI GWAS catalog
R = In LD with SNP replicated in at least one of the databases associated with references GTEx [1], Westra et al. [5], Liang et al. [6], Kirsten et al. [8]
All 25 cis-eQLTs and 25 trans-eQLTs are internally validated and have consistent sign of expression change
S = SNP-in-probe problem likely inflates R2
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specific genes. In addition, Cluster 1 may contain an un-
discovered platelet-associated variant, as it is associated
with enrichment for platelet-related genes.
We also identified several trans-eQTL clusters that
target trans-eGenes related to other blood cell types. For
example, seven clusters (17, 18, 25, 49, 51, 54, and 59;
Table 5) appear to target expression of six to 27 genes
specific to CD71+ early erythrocytes or reticulocytes
[21] (significantly enriched, Fisher’s exact test P values
1.8E-33 to 1.2E-7). Of these, three (Clusters 17, 18, and
25 on chromosomes 6 and 7) contain SNPs with known
associations in GWAS with red blood cell traits, including
hematocrit and hemoglobin (e.g. rs668459 on chromo-
some 6 [22] and rs12718597 on chromosome 7 [23]).
Thus, these clusters may arise from effects of the genetic
variant on hematopoiesis or related pathways.
Fourteen of the clusters include eQTL-gene pairs that
have been observed in previous studies [5–8] of whole
blood or the peripheral blood mononuclear cells
(PBMC) fraction (Table 5, Column 8), including Clusters
4, 6, 10, 11, 17, 18, 25, 29, 33, 34, 35, 38, 39, and 51.
Eight of the 13 previously mentioned GWAS platelet-
related clusters are among these. Another, Cluster 6,
targets 18 trans-eGenes (seven previously validated) and
contains GWAS hits for blood-related diseases and
traits. Two more (Clusters 11 and 29) show enrichment
of neutrophil-specific target genes. Clusters 18 and 25
include GWAS SNPs for mean corpuscular volume (e.g.
rs668459 and rs12718597, respectively) and are enriched
in reticulocyte specific target genes. Finally Cluster 35
with eight trans-eGenes, of which three are validated
(Table 5, Additional file 1: Table S7), includes GWAS
hits for melanoma and response to metformin, but the
relationship of these eight genes to either phenotype is
unclear.
Target genes of trans-eQTL clusters may suggest
mechanism of action
Clusters might arise as a result of factors other than
changes in proportion of blood cell types. Examination
of the sets of target genes of trans-eQTL clusters
(Additional file 1: Table S7) may suggest a functional
mechanism at play in the regulation of trans-eGenes.
We found examples of enrichment of genes annotated
as targets of transcription factors, as targets of micro-
RNAs (miRNAs), and for several signaling pathways
(Table 5, Gene set enrichment analysis (GSEA)). Some
trans-eQTL clusters target transcripts [24] sharing a
common promoter binding site motif [24], suggesting
that certain transcription factor pathways are modified
by genetic variants within the cluster (Additional file 1:
Table S8). For example, Clusters 10 and 51 target an
over-abundance of genes with promoter regions con-
taining motifs specific to transcription factors SP1 and
NRF1. Indeed, transcription factor SP1 has recently
been shown to regulate platelet formation in mouse
[25]. Changes in activities of these transcription factors
may mediate the effect of genetic variants in these
clusters on platelet formation and dynamics.
miRNAs may mediate effects of trans-eQTLs
miRNAs that are encoded near an eQTL and bind to a
trans-eGene might be a part of the mechanism under-
lying trans-eQTLs, as miRNAs are known to modify the
expression or degradation of their target mRNAs. GSEA
[26] of the genes targeted by each cluster revealed that
variants in several clusters target a significant number of
genes that are themselves targets of specific sets of
miRNAs (at FDR < 0.05; Additional file 1: Table S9). For
example, Cluster 51 targets the expression of 141 genes
Fig. 2 Box plots of very strong cis-eQTL or trans-eQTL-transcript cluster
pairs. a rs2499412 – TMEM164 (cis, R2 = 47%). b rs3773654 – PEX11A
(trans, R2 = 16%). y-axis: expression level in RMA units; x-axis: imputed
major allele count
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(Additional file 1: Tables S6 and S7) including 13 genes
(PPM1A, TSPAN5, APP, PIM1, COPS2, CSDE1, WDTC1,
AP2A1, CARM1, FURIN, EPB49, FAM134A, and
SH3BGRL2) known [26] to be targets of a small set of
miRNAs (miR-15A, miR-16, miR-15B, miR-195, miR-424,
miR-497), a highly significant enrichment (FDR < 0.0001).
Access to the measured miRNA expression data from the
same whole blood samples [27] allowed us to compare the
expression levels of five of these six miRNAs (miR-497
was not measured) with expression levels of the 13 genes.
We found that all of these gene expression levels, except
CSDE1, were correlated with expression levels of each of
the five measured miRNAs (genome-wide FDR < 0.001).
In addition, 119 of the 141 mRNA levels targeted by
Cluster 51 were correlated with measured levels of at least
one of these miRNAs at FDR < 0.001 (Additional file 1:
Table S9). This provides suggestive evidence that one or
more of these miRNAs may be involved in the mechanism
of action of the corresponding genetic variants.
Cluster 39 contains SNPs associated in GWAS with
almost two dozen traits or diseases (Additional file 2:
Table S10) and trans-eQTLs targeting a similar number
of distinct genes. The variant rs3184504 within SH2B3
on chromosome 12 and its proxy rs653178 lie within
this cluster and were previously observed to be cis-
eQTLs for SH2B3 and trans-eQTLs for six interferon-γ
signaling transcripts and nine toll-like receptor signaling
genes [5]. In our study, these two SNPs are associated
with the trans expression levels of four of six previously
reported [28] interferon-γ signaling genes and with five
additional genes (GBP3, GBP5, GBP7, FCGR1A, and
FCGR1B). We confirmed only one of nine previously re-
ported toll-like receptor signaling genes, possibly a result
of differences in the expression measurement platforms
employed. Also, we found a much stronger cis associ-
ation of rs3184504 with ALDH2 and OAS2 compared to
SH2B3, although the latter harbors this eQTL in its
coding region.
Comparison to published trans-eQTL blocks or clusters
A recent study of human eQTLs in blood-derived RNA
also noted extensive clusters of trans-eQTLs. Kirsten et
al. [8] reported finding almost 849 unique trans-eQTLs
with two or more targets, corresponding to about 175
loci. Our more restrictive definition of a trans-cluster re-
quiring six or more trans-targets identified 753 trans-
eQTLs in 59 loci or trans-clusters. However, the overlap
of these two approaches was not extensive. Among our
59 trans-clusters of eQTLs, we found 14 harboring
eQTLs also found by Kirsten et al. [8], with one or more
of the identical targets (Table 5, Additional file 1: Figure
S6). Of these, 12 could be readily identified as related to
platelets or red blood cell components by the GWAS
hits they contained. Of the remaining two clusters, Clus-
ter 29 contains no GWAS related traits, but includes tar-
gets related to neutrophils. Cluster 35 includes GWAS
hits for melanoma and response to metformin but is
otherwise cryptic.
Kirsten et al. [8] highlighted ten eQTLs, each in LD
with one or more GWAS hits and each with at least
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three, mostly novel, associated trans-eGenes. Of these,
one (rs10512472) falls into our Cluster 51, the second
strongest platelet-related cluster, for which we found 141
trans-eGenes including five of the nine target genes
found in their study. Overall, we provide strong support
for only one of their ten highlighted trans-clusters. This
modest level of replication might be attributable to dif-
ferences in the underlying cohorts, differences in the tis-
sue RNA source, or other technical factors, or may point
to platform-specific limitations in defining trans-clusters
themselves.
Trans-eQTLs not in clusters
Some of the trans-clusters, e.g. clusters 18 and 25, may
be the direct result of variation of cell type in the whole
blood samples, such as reticulocyte content, for which
inadequate data were available to compensate. However,
of the 5749 lead trans-eQTLs (Table 2), 90% (5212) are
not found in any of our trans-clusters, suggesting that
the majority of detected trans-eQTLs are not simply the
result of uncompensated cell type variation. Rather,
other mechanistic explanations should be sought, includ-
ing cis-expression of transcription factors or miRNAs not
measured in our assay, or other rarer transcribed mole-
cules such as long non-coding RNAs having as yet un-
identified effects elsewhere in the genome. Of the 5212
trans-eQTLs not found in clusters, 15 are found in the
GWAS catalog [14] (Additional file 2: Table S10) but only
a small fraction (15 of 5212 or 0.2%) were validated in
earlier studies, although many were internally validated.
Clinical relevance
Among 7057 SNPs that were associated (at P < 5E-8)
with 942 phenotypes in the NHGRI-EBI GWAS Catalog
[14], 3381 or 48% were significant eQTLs, related to 654
distinct phenotypes. This coverage represents two times
the number expected by chance (1696, P < 2E-16, Fish-
er’s exact test). Limiting our results to only the lead
eQTLs and variants with > 80% LD, we saw smaller but
more significant coverage of 15% (observed 1028, ex-
pected 367, P < 2E-277). Of these 1028 lead eQTLs, 922
(or 13%), were cis-eQTLs; 200 (or 3%) were trans-
eQTLs. The full list of eQTL GWAS hits is provided in
Additional file 2: Table S10. The significant coverage of
the GWAS Catalog makes our eQTL library valuable for
exploring hypotheses regarding putative functional
mechanisms.
The CARDIoGRAMplusC4D consortium completed a
GWAS meta-analysis of 60,801 coronary artery disease
or myocardial infarction (CAD/MI) cases and 123,504 con-
trols and identified 58 genomic loci associated with CAD/
MI [29]. Solid explanations for individual mechanisms of
effect, however, were provided for only a handful of these
loci. When the risk variant lies in the exon of a gene or its
UTR, it is likely that the host gene is in the effect pathway.
However, only four of the 58 CAD/MI GWAS SNPs
reside in the exons or UTRs of genes (Additional file 1:
Table S11). Two of these are missense variants (rs3184504
in SH2B3 and rs11556924 in ZC3HC1). The polymorphism
rs964184 lies in the 3’ UTR of ZPR1 and rs7528419 lies in
the 3’ UTR of CELSR2 and downstream of SORT1.
Musunuru et al. [30] demonstrated that rs12740374, a per-
fect proxy for the risk variant rs7528419, is responsible for
changes in SORT1 expression in liver and alters plasma
LDL-cholesterol levels in mouse. For 36 CAD/MI associ-
ated loci, the lead risk variants reside in intronic regions of
genes, making their contribution to the effect pathways less
clear, though expression level or transcript splicing vari-
ation might play a role. For the remaining 18 loci, the lead
risk variants fall tens to hundreds of kilobases from the
nearest gene. Several of the nearest genes, such as LDLR at
the 19p13.2 locus, encode proteins with known roles in the
biology of CAD/MI, such as lipid metabolism or regulation.
Others, such as the lead risk variant for the PMAIP1-
MC4R locus are close to known obesity risk variants.
Nikpay et al. [29] also noted that a cluster of such genes
with documented roles in vessel wall biology can be identi-
fied among their CAD/MI GWAS results.
We posit that eQTLs can aid in identifying causal
genes or pathways represented by “risk SNPs” from
GWAS. Indeed, 19 of the 58 CAD/MI risk loci were pre-
viously reported by Nikpay et al. [29], Schunkert et al.
[31], and the CARDIoGRAMplusC4D Consortium [32]
to contain cis-eQTLs for nearby eGenes. The roles of
several of the targeted eGenes have been confirmed in
animal or in vitro experiments. For example, rs264 at
8p21.3, intronic to LPL (lipoprotein lipase), correlates
with LPL expression in monocytes [32]. Mutations in
LPL cause LPL protein deficiency resulting in type 1
hyperlipoproteinemia [33]. rs264 is also strongly associ-
ated with circulating triglyceride and HDL cholesterol
levels [34].
We performed a comprehensive eQTL analysis of
these 58 CAD/MI risk loci by intersecting the published
GWAS SNPs with the significant eQTLs in our study
and identified candidate causal genes for 21 (36%) of the
risk SNPs. Eleven CAD/MI risk SNPs or a SNP in strong
LD with them, were also lead eQTLs in our study. An-
other ten CAD/MI risk SNPs were found to be signifi-
cant eQTLs, but not the lead eQTL at that locus (see
“Methods”). We confirmed that ten genes at nine loci
mentioned in Nikpay et al. [29] were targeted by cis-
eQTLs, specifically at the ABO, IL6R, LDLR, LPL, REST-
NOA1, SORT1, SWAP70, UBE2Z, and VAMP5-VAMP8-
GGCX loci (Additional file 1: Table S12). These cis-eQTLs
were highly significant, with P values ranging from
4 × 10−5 to <10−300 and often coincided with or were
in extremely strong LD with a lead eQTL in our
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study. However, since our study was based on RNA
derived from whole blood, failure to confirm previously
observed eQTLs may stem from the tissue specificity of
expression control [1].
Among the 58 GWAS SNPs for CAD/MI, we found 24
more cis-eQTL-eGene pairs (Additional file 1: Table S12)
not mentioned by Nikpay et al. [29]. The strongest (P <
1E-455) eQTL, rs1412445, is in the third intron of LIPA
(lipase A) transcript variant 1 and was a cis-eQTL for
LIPA expression. This eQTL was described by Wild et al.
[35] who attributed its effect on CAD through endothelial
dysfunction. Lipase A catalyzes the hydrolysis of choles-
teryl esters and triglycerides. Mutations can result in LAL
deficiency, a disease leading to dyslipidemia and choles-
teryl ester storage disease [33]. A link of LAL deficiency to
premature heart disease and stroke has also been reported
[36]. The second strongest of these eQTLs is rs149268645
in the WDR12 locus, a perfect proxy of the risk lead vari-
ant for the CAD/MI risk variant rs6725887. This eQTL
targets FAM117B (P < 1E-80), although it is not a lead
eQTL for this gene. Another perfect proxy cis-eQTL at
this locus (rs149846585) targets expression of CARF (or
ALS2CR8, P < 1E-40) and is the lead eQTL for that gene.
The third strongest (P < 1E-53) eQTL, rs11191582, is in
strong LD with the risk variant rs11191416 in the
CYP17A1-CNNM2-NT5C2 locus and targets the expres-
sion of NT5C2, although the eQTL is not the lead eQTL
for that gene. NT5C2 was recently described as a cis-
eQTL target in the context of aneurysm susceptibility
[37]. At this same locus, our cis-eQTL, rs4409766 target-
ing AS3MT was also found by Pierce et al. [38] in the con-
text of arsenic metabolism. Our cis-eQTL rs17115100
targeting WBP1L was also found for this locus (Additional
file 1: Table S12). We also identified potentially novel,
strong cis-eQTLs for SNF8 and ATP5G1 at the UBE2Z
locus, and OAS2 at the SH2B3 locus where the CAD/MI
GWAS risk SNP was in very strong LD with our lead
eQTL (Additional file 1: Table S12).
Two very strong cis-eQTLs were confirmed at the
VAMP5-VAMP8-GGCX locus, targeting cis-eGenes
VAMP8 and GGCX. The CAD/MI risk SNP rs7568458
was in tight LD with our lead eQTL for VAMP8 and for
GGCX. The gene GGCX codes for a protein that
carboxylates glutamate residues of vitamin K-dependent
proteins and in turn can affect coagulation and may pre-
vent of vascular calcification and inflammation [33].
Thus, a hypothetical causal pathway leading to inflam-
mation may be triggered by variants at this locus, in
particular through variation in one or both cis-eGenes.
The lead CAD/MI risk SNP at the VAMP5-VAMP8-
GGCX locus (rs7568458) was also in tight LD with
trans-eQTLs targeting five eGenes (CASP5, DPEP3,
CRISPLD2, SLC26A8, PKN2; Additional file 1: Table S12).
The trans-eGene, CASP5, expression level was previously
shown to be associated with blood pressure [39]. The
VAMP5-VAMP8-GGCX locus itself coincides with our
trans Cluster 7 (Table 5). The top GSEA term for the
eGenes in this cluster was “neutrophils” (Table 5) suggest-
ing that the trans-eGenes associated with this cluster are
associated with altered neutrophil concentration or activ-
ity. Thus, possibly multiple causal pathways may operate
here, one through cis-eQTL activity on VAMP8 and
GGCX, and another through one or more of the trans-
eGenes such as CASP5.
The CAD/MI GWAS risk SNP rs3184504 at the
SH2B3 locus is in tight LD with a cis-eQTL targeting the
expression of OAS2 and SH2B3, and also is in tight LD
with trans-eQTLs targeting 16 trans-eGenes (Additional
file 1: Table S12). The SH2B3 locus coincides with our
trans Cluster 39 (Table 5). The Top GSEA categories for
the 17 trans-eGenes in Cluster 39 include interferon sig-
naling, cytokine signaling, and immune system (Table 5).
The SH2B3 CAD/MI GWAS risk SNP resides in a
GWAS hot spot, showing strong associations with nu-
merous diseases and phenotypes including red blood cell
traits, platelet volume, and eosinophil counts, as well as
CAD, blood pressure, and stroke [14]. Using the same
eQTL data, Huan et al. [39] extensively studied lead
variant rs3184504 in the context of blood pressure and
found SH2B3 to be a “key driver” gene of a blood pres-
sure gene regulatory network. They found that many of
the trans-eGenes for rs3184504 were themselves signifi-
cantly related to blood pressure. It is interesting to note
that one of these hypertension-related trans-eGenes,
ATP2B1, is also a cis-eGene of the lead CAD/MI GWAS
risk SNP at the ATP2B1 locus (Additional file 1: Table S12).
Thus, the pathways implicated in hypertension at the
SH2B3 locus may intersect with pathways at the
ATP2B1 locus.
We were able to confirm that REST is a target of a cis-
eQTL in the REST-NOA1 locus on chromosome 4. How-
ever, we also observed that the CAD/MI GWAS SNP at
this locus, rs17087335, is in tight LD with lead trans-
eQTLs targeting expression of trans-eGenes GDAP1
(ganglioside induced differentiation associated protein
1 on chr 8; P < 1E-20) and CACNA1E. (calcium voltage-
gated channel subunit alpha1 E on chr 1; P < 1E-7,
Additional file 1: Table S12). We speculate that these
trans-eQTLs may point to a molecular mechanism
underlying this CAD/MI risk locus.
Molecular QTL browser
To make our results more user-friendly and accessible,
we have made them freely available via the NCBI Mo-
lecular QTL Browser (https://preview.ncbi.nlm.nih.gov/
gap/eqtl/studies/), which serves as a resource for data on
association between genetic variation and molecular
phenotypes. The browser links our results to multiple
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resources including eQTLs identified in other studies.
Importantly, users may specify P value cutoffs and other
filtering criteria. Users of the Molecular QTL Browser
may conduct targeted studies of specific genes based on
prior evidence or may wish to do meta-analysis of mul-
tiple eQTL studies, where more permissive P value cut-
offs may be appropriate. To support meta-analysis and
other comparisons across primary studies, the integrated
data resource allows for cross-dataset searches and
filtering based on genome location or functional an-
notation (Fig. 4).
Discussion
We provide the largest, single study and database of cis-
eQTLs and trans-eQTLs to date. We considered several
examples of the potential implications of our results for
interpreting GWAS findings. Our results also can be
used to guide functional studies such as targeted gene
knockout experiments and studies of miRNA expression
in follow-up of GWAS results. We have illustrated how
extensive cis-eQTL and trans-eQTL data can be used to
augment GWAS analysis of a complex disease (CAD/
MI). Of the 58 recently reported lead risk variants for
CAD/MI [29], we show that 21 contain cis-eQTLs tar-
geting 34 genes. Four additional risk variants are trans-
eQTLs targeting 24 eGenes. Thus, eQTL analysis can
provide a rich resource for defining putative causal path-
ways of risk variants determined in GWAS.
Our genome-wide trans-eQTL results provide a new
richness of detail regarding trans-eQTL clusters and
their putative relations to various transcription factors
and miRNA targets. Another group [8] recently also car-
ried out a genome-wide trans-eQTL analysis, providing
a basis for comparison of our complete trans-eQTL
results. However, their use of a different tissue (PBMC-
derived RNA rather than whole blood), use of a different
expression platform (an Illumina array rather than the
Affymetrix Human Exon Array), and imputation to a dif-
ferent SNP set (HapMap II rather than 1000 Genomes),
limit the value of comparisons and explain the low rate
of validation (6%).
Although many of the trans clusters may have resulted
from uncompensated variation in cell type in the whole
blood samples, some clusters could not be so easily ex-
plained. Moreover, a large majority (90%) of the lead
trans-eQTLs did not appear in any cluster, including
nine of our top 25 lead trans-eQTLs. Thus, we have
identified a large number of trans-eQTL whose mechan-
ism of action is likely not simply due to cell proportion,
but through other mechanisms possibly involving miR-
NAs, transcription factors, long non-coding RNAs, or as
yet unidentified transcribed molecules.
Fig. 4 Screenshot of NCBI molecular QTL browser
Joehanes et al. Genome Biology  (2017) 18:16 Page 15 of 24
The exon-level expression data permitted us to iden-
tify more precisely cases of polymorphism-in-probe,
where the genetic variant is directly detected by the ex-
pression array and might easily be interpreted as an as-
sociated change in overall gene expression. The same
exon-level expression data facilitated a search for spli-
cing variants influenced by genetic sequence (sQTLs)
[40]. However, the additional noise inherent in the exon-
level analysis offsets to some degree the benefits of the
additional resolution offered by measuring exon-specific
expression.
Our findings on cis-eQTL patterns are generally con-
sistent with previous findings. We were able to validate
54–58% of our lead cis-eQTL results compared to other
studies using microarrays. For a study using next-
generation sequencing, the validation rate dropped to
25%. Only about 3–6% of our lead trans-eQTL results
could be found in previous studies, possibly reflecting
the need for very large sample size when generating
trans results or the dependence on the specific expres-
sion platform and tissue being studied. Conversely, we
were able to replicate a substantial proportion of previ-
ously published eQTL results (up to 69% for cis and up
to 10% for trans-eQTL-gene pairs). Two previous studies
[5, 6] have the limitation of combining, via imputation,
genotypes from multiple platforms, which might lead to
variation in imputation quality across SNPs. We used a
single platform with approximately 550 K markers and
successfully imputed 8.5 million SNPs. The study of
Liang et al. [6] used two less dense genotyping platforms
having approximately 100 K and 300 K markers; thus, it
is not surprising that we found many more eQTLs espe-
cially in regions where our denser genotyping array pro-
vided better marker coverage. The genotype array used
in the RNAseq-based study [7] was denser than our
genotyping array, but the authors did not impute results
to the denser 1000 Genomes SNP set. We were able
both to replicate and extend the impressive findings of
Westra et al. [5]. In our Cluster 39, which contains the
highly pleiotropic GWAS SNP rs3184504, Westra et al.
[5] observed multiple gamma interferon signaling genes
and multiple toll-like receptor signaling genes as tar-
gets of this trans-eQTL. We were also able to identify
this strong trans-eQTL and extend its associated
transcript list to five additional interferon signaling
genes.
The strengths of our study include its large sample
size, expression measurement carried out in a single
laboratory with rigorous quality control, use of imput-
ation to a dense set of 1000 Genomes SNPs, and extensive
attention to controlling for artifacts in the expression data.
As a consequence, we found that a substantial proportion
of published GWAS SNPs associated with traits or
diseases are themselves lead eQTLs for nearby (13%)
or distant (3%) genes. We determined that our full
sample size detected 60% more target genes than did
a subset of about half the original size, showing that
many previously undetected eQTLs and target tran-
scripts are probably newly detected with our study
and that even more eQTL-eGene pairs remain to be
discovered.
The very large proportion of variance explained (R2)
values for the strongest eQTLs (up to 57% for cis and
up to 22% for trans, Table 4), pointing to the very large
influence that these variants can have on expression
levels. Such high R2 values may also arise due to
polymorphism-in-probe instances, but we used an ef-
fective procedure for detecting such cases. Of course, it
is possible that as yet undiscovered SNPs exist on
probes and are responsible for some of these extreme
R2 values.
A further strength of our study is that the expression
array contains far more probes and probesets than the
arrays used in some other eQTL studies. For example,
the array used in the meta-analysis of Westra et al. [5]
(Illumina Human HT12) contains about 49,000 probe-
sets, whereas the gene expression platform of this
study, the Affymetrix Human Exon Array, contains
almost six times more probesets. The additional
probesets allow for the detection of expression
changes along the entire length of the transcript, rather
than primarily near its 3’ end. These extra probesets also
give added protection against polymorphism-in-probe
artifact by averaging across the many probes for each
transcript.
In addition to conducting this large genome-wide
eQTL study, we have created a public resource of cis-
eQTLs and trans-eQTLs at the gene and exon level. Our
results are based on a much larger cohort than any pre-
vious public eQTL resource, and therefore reflects a
higher degree of precision and specificity of eQTLs,
eGenes, and eQTL-eGene pairs.
We acknowledge several limitations of our study. The
homogeneity of the FHS population may limit the
applicability of our results to populations of different
ancestries. Lack of population diversity might also in-
crease the size of LD blocks and thereby limit the reso-
lution with which true regulatory sites can be identified.
Despite statistical adjustments for imputed blood cell
counts, our eQTLs might still reflect cell type admixture
effects and might not be comparable to results obtained in
other tissues. RNAseq-based methods for determining
gene expression offer even higher resolution and may not
be subject to the same biases accompanying microarray
measurements. However, agreement of our study with a
recent RNAseq-based study [7] was comparable to the
level of agreement seen with several other microarray-
based studies.
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Conclusions
Despite these limitations, our results provide an exten-
sive resource of cis-eQTLs and trans-eQTLs at the gene
and exon level and this information may be useful for
elucidating the biological underpinnings of many GWAS
SNP associations with disease traits. Our eQTL database
will facilitate better understanding of novel pathways
and associations across the human genome, which may
contribute to new approaches for the detection, treat-
ment, and prevention of diseases.
Methods
Study participants
Recruitment procedures and clinical characteristics of
participants from the FHS Offspring [10] and Third
Generation cohorts [11] have been reported previously.
Samples for this study came from 2770 individuals who
attended the eighth Offspring cohort examination cycle
(2005–2008) and 3341 individuals who attended the
second examination cycle (2006–2009) of the Third
Generation cohort. Protocols for participant examina-
tions and collection of genetic materials were approved
by the Boston Medical Center Institutional Review Board.
All participants gave written, informed consent.
Isolation of RNA from whole blood, preparation, and
hybridization
Fasting peripheral whole blood samples (2.5 mL) from
FHS participants were collected during examination
in PAXgene™ tubes (PreAnalytiX, Hombrechtikon,
Switzerland), incubated at room temperature for 4 h
for RNA stabilization, and then stored at −80 °C.
Total RNA enriched with miRNA was isolated from fro-
zen PAXgene blood tubes by Asuragen, Inc., according to
the company’s standard operating procedures for auto-
mated isolation of RNA from 96 samples in a single batch
on a KingFisher® 96 robot. Tubes were allowed to thaw for
16 h at room temperature. After centrifugation and wash-
ing to collect white blood cell pellets, cells were lysed in
guanidinium-containing buffer. Organic extraction was
performed prior to adding binding buffer and magnetic
beads in preparation for the KingFisher run. The purity
and quantity of total RNA samples were determined by
absorbance readings at 260 and 280 nm using a Nano-
Drop ND-1000 UV spectrophotometer. The integrity of
total RNA was qualified by Agilent Bioanalyzer 2100
microfluidic electrophoresis, using the Nano Assay and
the Caliper LabChip system.
Preparation of complementary DNA from RNA
RNA samples of 50 ng were amplified using the WT-
Ovation Pico RNA Amplification System (NuGEN, San
Carlos, CA, USA) as recommended by the manufac-
turer in an automated manner using the genechip
array station (GCAS). In brief, first strand complemen-
tary DNA (cDNA) was prepared using a unique first
strand DNA/RNA chimeric primer mix and reverse
transcriptase. In the second step, DNA/RNA Hetero-
duplex Double Stranded cDNA was generated which
served as the substrate for SPIA amplification – a lin-
ear isothermal DNA amplification process developed
by NuGEN. In the third step, amplified DNA along
with RNA was treated with RNase H to degrade the
RNA in the DNA/RNA heteroduplex at the 5’ end of
the first cDNA strand which then served as the initi-
ation site for the next round of cDNA synthesis. The
process of SPIA DNA/RNA primer binding, DNA rep-
lication, strand displacement, and RNA cleavage is re-
peated, resulting in rapid accumulation of microgram
amounts of SPIA cDNA. An aliquot of the SPIA cDNA
was used for quantitative polymerase chain reaction
(qPCR) analysis.
Target labeling and hybridization onto Affymetrix
Genechips
Three micrograms of the amplified cDNA from the WT-
Ovation Pico amplification step were processed with the
WT-Ovation Exon Module in GCAS to produce sense
strand ST-cDNA following the manufacturer’s (NuGEN,
San Carlos, CA, USA) procedure; 5 μg ST-cDNA was
fragmented and labeled with the FL-Ovation™ cDNA
Biotin Module using a proprietary two-step fragmenta-
tion and labeling process. The first step is a combined
chemical and enzymatic fragmentation process that
yields single-stranded cDNA products in the base range
of 50–100 . In the second step, this fragmented product
is labeled via enzymatic attachment of a biotin-labeled
nucleotide to the 3-hydroxyl end of the fragmented
cDNA generated in the first step. Hybridization, wash-
ing, and laser scanning of Affymetrix Human Exon 1.0
ST microarrays were performed according to the manu-
facturer’s protocol (Affymetrix, Santa Clara, CA, USA).
Hybridization was performed at 45 °C overnight,
followed by washing and staining using FS450 fluidics
station. Scanning was carried out using the 7G GCS3000
scanner.
Affymetrix human exon 1.0 ST microarray platform
This platform consists of approximately 6 million 25
base probes, grouped into about 300,000 four-probe pro-
besets, each designed to target an exon of a transcript.
Multiple probesets are grouped together to represent a
set of transcripts from a single gene (called a transcript
cluster). Transcript clusters are annotated to genes in a
nearly one-to-one fashion. Transcript clusters have from
one to several hundred probesets, depending on the
length of the transcript, and form the basis of our
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analysis here. Of the 12,396 transcript cluster IDs which
are found to be eGenes (either cis- or trans-), only 244
are in a many-to-one relationship with an EntrezGene
and 282 no longer map to an Entrez gene entry. Thus, a
transcript cluster level analysis may be considered a
proxy for a gene-level analysis.
Microarray data collection, quality control, and data
adjustment
The intensity values for each gene chip were collected
using the robust multi-chip average (RMA) method
available in the Affymetrix Power Tools (APT) [41] Soft-
ware version 1.12.0 (Affymetrix). A total of 287,329
Refseq-core [42] probesets representing 17,873 distinct
genes from 6111 samples were extracted from the APT,
based on NetAffx annotation version 31 [43]. Samples
were excluded based on three factors: (1) values for a
quality control (QC) metric, all_probeset_rle_mean ≥ 0.7
[44]; (2) chromosome Y-linked gene expression did not
agree with reported sex; and (3) when a DNA/mRNA
sample pair mix-up is apparent, based on the top 395
eQTLs with minor allele frequency (MAF) ≥ 0. The
remaining 5626 samples with satisfactory results consti-
tuted the study samples and were again normalized with
RMA, retaining only core-level probesets. We deter-
mined that many artifacts in the expression data could
be reduced by adjusting for chipping batch, various tech-
nical factors provided by Affymetrix APT program for
each array hybridization, and for the first principal com-
ponent (PC1) determined from the centered and unscaled
RMA data. The technical adjustment factors were: all_
probeset_mean, all_probeset_stdev, neg_control_mean,
neg_control_stdev, pos_control_mean, pos_control_stdev.
all_probeset_rle_mean, all_probeset_mad_residual_mean,
and mm_mean. In addition, we adjusted by Probeset-
GroupDiff, which partially accounts for the non-random
layout of probes on the Affymetrix Exon Array.
Several additional data adjustments were considered
beyond the technical covariates described above. We
tested the effects of: (1) including 40 PCs on the un-
adjusted data; (2) including 20 PEER factors [45] on the
unadjusted data; (3) including 20 PEER factors on the
adjusted data; and (4) including 40 surrogate variables
[46] on the un-adjusted data. The internal validation rate
for cis-eQTLs (Additional file 1: Table S2) was greatest
when 20 PEER factors were used with the adjusted
data and this approach was selected as the method of
choice.
Genotyping platform and SNP imputation
Of the 5626 microarray samples passing quality controls,
5257 were previously genotyped using the Affymetrix
500 K and MIPS 50 K platforms [47, 48]. From a total
number of 549,781 genotyped SNPs, we removed
137,728 genotyped SNPs on the following filtering cri-
teria: Hardy–Weinberg Equilibrium (HWE) P value < 1E-6
(22,018 SNPs), call rate < 96.9% (48,285 SNPs), MAF < 0.01
(66,063 SNPs), map mismatch from Build 36 to Build 37
(82 SNPs), missing a physical location (428 SNPs), number
of Mendelian errors > 1000 (25 SNPs), residing outside
of chromosomes 1–22 or X (786 SNPs), and duplicates
(41 SNPs). This leaves the remaining 412,053 SNPs as
input to Minimac [49], an implementation of genotype
imputation software, MACH [50]. The 1000-Genomes
“cosmopolitan” SNP set [51] was used as the imput-
ation reference platform. Minimac’s GIANT 1000 Ge-
nomes Imputation protocol was used, with the SNP
phasing options of: −rounds 20 –states 200 –phase –sam-
ple 5, yielding a total of 39,315,185 SNPs. Of these, we
chose SNPs with imputed quality score (R2) ≥ 0.3 and
MAF ≥ 0.01, leaving a total of 8,510,936 SNPs for analysis
of cis and trans association, all in hg19 coordinates. The
genotyping data are available in dbGaP under study
phs000342.v13.p9 (http://www.ncbi.nlm.nih.gov/projects/
gap/cgi-bin/study.cgi?study_id=phs000342), which is
under the umbrella of the overall FHS study of
phs000007.
We performed a principal component analysis (PCA)
with 521 unrelated FHS participants (Additional file 1:
Figure S7) along with HapMap individuals (CEPH with
Northern and Western European ancestry (CEU, Pink),
Yoruba from Ibadan, Nigeria (YRI, Red), Han Chinese
from Beijing (CHB), and Japanese from Tokyo (JPT).
The samples which entered the eQTL study are shown
in Additional file 1: Figure S7. The program smartpca
from the EIGENSOFT package was used to perform the
PCA [52]. PCs for additional FHS participants were
computed from the PC weights derived from that
analysis.
We also charted the effect of imputation R2 on
validation rates for that eQTL (Additional file 1:
Figure S8). Validation rate rises nearly linearly with
imputation R2 from about 58% (R2 < 35%) to ~69%
(R2 > 85%). However, since the overall average imput-
ation R2 for this set is 94%, the lowered validation
rate for lower quality imputation has little impact on
the final result.
Whole blood cell counts
Of the 5257 samples, 2181 from the Third Generation
cohort had whole blood complete blood cell counts
(CBCs, Beckman Coulter, Brea, CA, USA). The cell
counts of the remaining samples were imputed using a
partial least squares (PLS) prediction based on the gene
expression data. Cross-validated estimates of prediction
accuracy (R2) for the CBC components (WBC, RBC, plate-
let, neutrophil percent, lymphocyte percent, monocyte
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percent, eosinophil percent, and basophil percent) were
0.61, 0.41, 0.25, 0.83, 0.83, 0.81, 0.89, and 0.25, respectively.
We conducted comparisons between results of using
imputed cell counts and those when using measured
ones and did not find significant difference. Thus, we
used measured cell counts when available and imputed
ones when not.
Statistical analysis
An eQTL is defined to be any SNP with a significant as-
sociation to the expression level of some transcript.
The analysis required two phases: first, using the
mixed-effect modeling package pedigreemm [53] of R
version 3.0.1, we removed from the expression data (for
5626 samples) the effects of sex, age, platelet count,
white blood cell whole count, and imputed differential
count (percentages of lymphocytes, monocytes, eosino-
phils, and basophils), while accounting for reported fa-
milial relationships, and collected the residuals. Next, we
computed 20 factors using a Bayesian framework to infer
hidden confounding factors (PEER [45]) on the residua-
lized gene expression data. These PEER factors, along
with sex, age, and imputed effect allele dosage were used
fit to the ResidualizedExpression, in an additive linear
model for the 5257 samples:
ResidualizedExpression ¼ Mean þ Sex þ Age
þ Peer1 þ … þ Peer20
þ EffectAlleleDosage
The model fit was repeated for all 1.5 × 1011
SNP:transcript cluster pairs. The algorithm was imple-
ment using Graphical Processing Units (GPUs) to ac-
celerate the computation. We collected the effect
estimate (β), T-statistics, R2, log10 P values, and log10
of Benjamini–Hochberg’s [54] FDR for EffectAlleleDosage,
after accounting for the other covariates, for each associ-
ation with P values < 1E-4. The FDR computations for cis
and trans were performed separately. To check for the in-
fluence of possible apparent inflation of P values in just
the 2 Mb cis regions, we used the method of Devlin and
Roeder [12] to adjust the P values such that the genomic
control factor λ becomes 1.0. The FDR values for the de-
clared significant cis-eQTLs rose only slightly, but did not
exceed the stated cutoff of 5%.
Enrichment P value calculation
In calculating “enrichment,” i.e. observed number di-
vided by expected number, we accounted for the LD
structure of the available 8.5 million SNPs by first “pruning”
to obtain a set of independent SNPs. Expected num-
bers were obtained from the relevant 2 × 2 contingency
tables, using the pruned set as the basis of comparison,
thereby insuring that counts were from nearly independent
observations. The pruning was accomplished by first
ordering SNPs by the minimal P value of that SNP
with any gene in the eQTL database, followed by all
remaining insignificant SNPs. Starting with the first
SNP on the list, we prune subsequent SNPs with
LD > 0.3. We then consider the second remaining list
member and prune the rest of the list, and so forth until
we reach the end of the list. The LD was computed
between pairwise SNPs within the FHS dataset. This
resulted in a set of about 279,310 independent SNPs.
Definition of cis-eQTL, trans-eQTL, primary lead eQTL, and
secondary lead eQTLs
An SNP-transcript cluster pair is considered cis if the
SNP resides within 1 Mb of the TSS on the same
chromosome or if the SNP resides in a contiguous block
of eQTLs which includes the TSS. A contiguous block of
eQTLs targeting a single transcript cluster is a set of sig-
nificant eQTLs on the same chromosome with no in-
ternal gaps greater than 1 Mb. Such blocks ranged in
size up to 10 Mb. eQTLs that fall in blocks which did
not contain the TSS for its target transcript cluster were
defined as “trans.” The “lead eQTL” is the strongest
eQTL, judged by P value for association, in its block. A
secondary lead eQTL may be found for a particular
block (and particular transcript) by fitting the regression
model:
ResidualizedExpression ¼ Mean þ Sex
þ Age þ Peer1 þ … þ Peer20
þ EffectAlleleDosage primary lead eQTLð Þ
þ EffectAlleleDosage test SNPð Þ
for each test SNP in the current block that has low LD
correlation to the primary lead eQTL (R2 < 0.36). If the P
value for the coefficient of the best test eQTL is less
than 0.0001, we define this as a secondary lead eQTL.
This process is iterated, adding successive secondary
lead eQTLs to the regression model until no more low-
linkage SNPs are left or the P value of the test SNP is
above 0.0001. This method is similar to one suggested
by Powell et al., but allows the effects of all eQTLs to be
re-estimated at each step of the regression [55].
Internal replication analysis
Results were replicated in two phases: (1) internal repli-
cation using two subgroups within the FHS overall study
set; and (2) external replication based on published
eQTL datasets. In the internal replication stage, we used
the FHS Offspring cohort as the discovery dataset and
the FHS Third Generation cohort as the replication
dataset. We ran the exact same statistical analysis on
each dataset and required that the pair satisfy FDR < 5%
in both the discovery and replication datasets to be con-
sidered replicated. Since both datasets used the same
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platforms for genotyping and expression, matching
markers and transcripts (or probesets) were done
directly using the marker ID or the transcript cluster ID.
External replication and validation analysis
Calculation of external replication rates required that
the eligibility of a published eQTL-transcript cluster pair
be determined. For Westra et al. [5] and Liang et al. [6],
we matched markers reported in those studies by their
identifiers or their exact genomic positions, to the avail-
able markers in our study. We matched their transcript
probes by overlap of their exact genomic start and end
addresses with the Affymetrix transcript clusters. Repli-
cation rate, then, is the ratio of previously reported re-
sults that are found in our study to the previous results
eligible to be replicated in our study. For Battle et al. [7],
only gene-symbol not genomic location was reported,
which was matched to the annotated gene-symbol for
the Affymetrix transcript cluster. For Kirsten et al. [8],
transcripts were defined by Entrez IDs, which were
matched to the annotation of the Affymetrix transcript
cluster ID.
Calculation of validation rates starts with determin-
ation of which of our eQTLs and which of our tran-
scripts were eligible to be measured in the published
study. Validation rate is the number of eligible lead
eQTL-transcript cluster pairs in our results which are
also validated in the published study divided by the
number of eligible pairs. Validation is asserted when we
can find a SNP:transcript cluster pair in the external
study where the SNP has > 80% LD correlation with our
lead eQTL. For Multiple Studies [2, 4–6], we considered
a pair to be validated if it was validated by any one of
the studies. Since we did not have access to a complete
list of SNPs or of transcripts, measurement of which
passed quality control in each external study, we had to
make some assumptions about eligibility. To be eligible,
we required the SNP Rs ID or the SNP genomic address
to match exactly, and that the SNP be included in
HapMap version 3. We also required that the probes of
the transcript on the external study to overlap the
probes on the Affymetrix transcript cluster, without
regards to the annotated gene-symbols. More details are
included in Additional file 1: Supplementary Methods.
For Battle et al. [7] eligibility for validation was deter-
mined if the SNP was on the Illumina HumanOmni1-
Quad_v1 BeadChip which interrogated 1,124,584 SNPs
and the transcript was part of the NCBI v37.2 (a.k.a.,
hg18) H. sapiens reference genome. Since Battle et al. [7]
reported only the lead-eQTL per transcript, we defined
validation if our lead eQTL was in LD with theirs at
R2 > 80%. For Kirsten et al. [8] eligibility was derived
from a file (personal communication from H. Kirsten, 8/
31/2016) of which SNPs and which EntrezIDs were used
by them in detecting significant SNP-transcript cluster
pairs. We also asserted validation if our lead eQTL was
in LD with R2 > 80% with their results.
Our definition of validation did not consider the direc-
tion of change because many studies did not report that
direction or did not report which allele was considered
as the reference. Kirsten et al. [8] did report sufficient
information to make this comparison, however. We re-
ported the mean percentage agreement for all validated
lead eQTL-transcript cluster pairs or pairs where the
eQTL was in > 80% LD with our lead eQTL.
To determine expected numbers of validated pairs
under the random assumption, each study calculated the
ratio of number of eligible detected pairs to the possible
number of eligible cis-eQTL:transcript pairs in the exter-
nal study. Then, since our lead eQTLs were independent,
we multiplied this ratio by the number of eligible pairs to
be validated. P values for the overlap of ours and previous
studies were calculated from 2 × 2 contingency tables, sep-
arately for cis- and trans-. In every case, the P values based
on Fisher’s exact test were incalculably small and were not
separately reported.
Detection rates and validation rates rose with the
number of probesets available for each transcript or
transcript cluster (see Additional file 2: Table S10),
reaching a plateau when about 21 to 25 probesets were
available. A probeset consists generally of four 25 base
probes on the Affy Exon array. A transcript cluster con-
sists of from one to several hundred probesets. Relative
validation rates also rose with increasing expression level
(Additional file 1: Figure S9), suggesting that more
highly expressed genes are more reliably detected as tar-
gets of eQTLs.
Polymorphism-in-probe analysis
When a SNP appears in the microarray probe, it may
appear to modify the expression level of that gene, but
actually only modify the binding affinity of the RNA to
the probe itself. The Affymetrix Human Exon array is
uniquely suited to detecting this artifact since it in-
cludes multiple, typically ten, probesets per gene. SNPs
affecting the binding affinity at a single probe are un-
likely to affect the affinity at other probes, so artifactual
expression changes can be detected by comparing
exon-level expression to that of the entire gene. We de-
veloped a rule to distinguish artifactual from real eSNPs
as follows. A SNP located in an Affymetrix probe was
declared to be a likely artifactual cause of significance
if: (1) the association R2 for this SNP was high, greater
than 90% of the maximal R2 achieved by the lead eQTL,
in the gene-level analysis; and (2) the R2 in the exon-
level analysis for this SNP for its exon was greater than
95% of the maximal R2 achieved by any cis-SNP for any
of the exons in this transcript cluster. In such cases, all
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eQTLs for this transcript cluster (gene) were marked as
likely artifact since most would be in linkage disequilib-
rium to some extent, with the lead eQTL.
We downloaded the golden path track from the UCSC
Genome website for the Affymetrix Exon Array probes,
probesets, and transcript cluster addresses in hg19 coor-
dinates. We performed an overlap analysis between the
probe coordinates and the addresses of SNPs with im-
puted quality score (R2) ≥ 0.3 and MAF ≥ 0.01. We
counted the number of eQTL pairs and the number of
SNPs with such an overlap.
Determination of the genomic control factor
The computation of the genomic control factor would
have required storage of at least half of all results, which
we estimated at about 4 Petabytes for our dataset. Due
to such extensive storage requirements, we rather opted
to perform transcriptome-wide eQTL analysis on a
random subsample of 100,000 SNPs at the gene level
(17,873 transcript clusters). The SNPs were selected
from those with imputed quality score (R2) ≥ 0.3 and
MAF ≥ 0.01, and also within the HapMap SNP set. We
stored only the P values arising from this analysis. We
computed the genomic control factor λ as defined by
Devlin and Roeder [12]. Let F(∙) be the upper-tail cumu-
lative distribution function of χ2 with degrees of freedom
of 1. Then λ = F−1(median(P values))/F−1(0.5).
Intersection with NHGRI GWAS catalog
We downloaded NHGRI GWAS catalog [14] on 5 June
2016 and filtered out SNP-trait pairs with P values > 5e-
8, leaving 7057 unique SNPs covering 942 phenotypes.
We intersected the GWAS SNPs with our significant
eQTLs having FDR < 0.05 and with our lead eQTLs.
Trans-eQTL cluster definition
Trans-eQTLs sometimes appeared in narrow blocks or
clusters within the genome, affecting numerous distant
transcript clusters. To formally define these clusters, we
focused only on all SNPs having six or more trans asso-
ciations and excluded all associations that resided in the
same chromosome as the SNP. We use a modified K
nearest-neighbor (KNN) algorithm [56] as follows.
Starting with the lead trans-eQTL, i.e. the SNP with the
most significant association by P value as a centroid, we
considered successive eQTLs to the left and the right of
the starting SNP (but on the same chromosome) and de-
termined whether to include each new eQTL in the
growing cluster according to its “distance” from the clus-
ter. Let A be the set of eGenes targeted by the current set
of trans-eQTLs and B be the set of target eGenes of the
neighboring eQTL. We computed the distance d between
sets A and B, where d = 1 - |A∩B|/min(|A|,|B|), where |.|
denotes the size of the set. If d < 0.7, we combined the
neighboring eQTL with the current set of eQTLs into the
cluster. Once there are no further SNPs passing the dis-
tance cutoff, the eQTLs in the current cluster were re-
corded and the algorithm restarted with the next available
eQTL in the original chromosome not yet included in
clusters. The clustering process is iterated until all SNPs
on the original chromosome were considered. The clus-
tering process builds a set or block of nearby SNPs
which are trans-eQTLs for substantially the same set
of genes.
Gene-set enrichment analysis
We performed GSEA [26] to determine putative func-
tions of the genes of each trans-cluster. We used the on-
line “Investigate Gene Sets platform GSEA” at http://
software.broadinstitute.org/gsea/msigdb/annotate.jsp, which
computes overlaps of the submitted gene lists with a library
of pre-established gene lists and provides a significance in-
dicator for the degree of overlap. We selected all categories
(C1: positional gene sets, C2: curated gene sets, C3: motif
gene sets, C4: computational gene sets, C5: GO gene sets,
C6: oncogenic signatures, C7: immunologic signatures) and
collected all categories with FDR < 0.05. We separated the
categories that correspond to promoters, transcription fac-
tors, and miRNA targets.
Enrichment analysis for CD71+ genes
We gathered from the literature 166 gene symbols that
are known to be associated with the CD71+, early eryth-
rocytes, or reticulocyte transcript [21]. We performed
one-sided Fisher’s exact test to test for enrichment only
on clusters targeting six or more genes in common with
these 166 genes.
MiRNA data collection
The profiling of the miRNA expression, as described in
a previous study [27], was performed using the quantita-
tive real-time polymerase chain reaction (qRT-PCR)
using the same PAXgene Blood RNA samples from the
same set of individuals as in the mRNA expression pro-
filing. The qRT-PCR was performed using a high
throughput qRT-PCR instrument BioMark System (Flui-
digm, South San Francisco, CA, USA). Blanking was per-
formed for quality control purposes using the BioMark
dynamic array platform and pooled samples were repeat-
edly measured for chip to chip variability, showing excellent
reproducibility and no cross-contamination. Threshold
cycle (Ct) values as measured by the qRT-PCR instrument
were used as measurements of miRNA expression levels.
Since Ct values reflect the number of amplification cycles
required for the fluorescent signal to exceed the back-
ground level, low Ct values indicate higher expression of
miRNA, with values over 27 considered as missing due to
the possible oversaturation of PCR product.
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MiRNA-mRNA co-expression analysis
The log-2 transformed miRNA Ct values were normalized
and adjusted for isolation batch, RNA concentration, RNA
quality, and 260/280 ratio (defined as the ratio of the ab-
sorbance at 260 and 280 nm; measured using a spectro-
photometer). The co-expression analyses between mRNA
expression levels and miRNA levels were performed under
linear mixed model, adjusting for age, sex, and family
structure, using the lmekin function in the kinship pack-
age [57], on samples with both miRNA and mRNA (n up
to 5357). We excluded miRNA measured in fewer than
400 non-missing values. Genome-wide Benjamini and
Hochberg’s [54] FDR was used to correct for multiple
comparisons. Only results with genome-wide FDR < 0.001
were considered. The miRNA-mRNA co-expression data-
base is described in Huan et al. [27].
Cluster miRNA enrichment analysis
To obtain miRNA targets per cluster, we performed GSEA
analysis (on miRNA target category) on transcripts tar-
geted by each cluster. We filtered the GSEA results at
FDR < 0.05. GSEA may output multiple miRNAs for one
cluster. After the GSEA analysis, we confirmed our
findings to see if the miRNA-transcript cluster pair are
indeed observed in our miRNA-mRNA co-expression
database above. We reported the number of confirmed
transcripts per cluster.
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